Your browser doesn't support javascript.
The effects of adjunctive treatment with L-carnitine on monitoring laboratory variables in ICU patients: a double-blinded randomized controlled clinical trial.
Yahyapoor, Farveh; Keshani, Mahdi; Sedaghat, Alireza; Feizi, Awat; Clark, Cain C T; Bagherniya, Mohammad; Safarian, Mohammad; Badpeyma, Mohaddeseh; Norouzy, Abdolreza.
  • Yahyapoor F; Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Keshani M; Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Sedaghat A; Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Feizi A; Department of Anesthesiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Clark CCT; Biostatistics and Epidemiology Department, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Bagherniya M; Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, UK.
  • Safarian M; Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Badpeyma M; Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Norouzy A; Anesthesia and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Trials ; 24(1): 3, 2023 Jan 03.
Article in English | MEDLINE | ID: covidwho-2196413
ABSTRACT

BACKGROUND:

Critically ill patients must be monitored constantly in intensive care units (ICUs). Among many laboratory variables, nutritional status indicators are a key role in the prognosis of diseases. We investigated the effects of L-carnitine adjunctive therapy on monitoring variables in critical illness.

METHOD:

A prospective, double-blind, randomized controlled trial was implemented in a medical ICU. Participants were 54 patients, aged > 18 years, with multiple conditions, randomly assigned to receive 3 g L-carnitine per day or placebo, along with enteral feeding, for 1 week. Primary outcomes included monitoring variables related to nutritional status.

RESULT:

Of 54 patients randomly assigned, 51 completed the trial. Serum albumin (Alb) (P-value 0.001), total protein (P-value 0.003), and calcium (Ca) (0.044) significantly increased in the intervention vs. control group. Alanine transaminase (ALT) (0.022), lactate (<0.001), creatinine (Cr) (0.005), and international normalized ratio (INR) (0.049) decreased meaningfully in the intervention vs. control group.

CONCLUSION:

L-Carnitine supplementation in critically ill patients can improve several parameters including INR, Cr, ALT, lactate, Ca, Alb, and total protein. TRIAL REGISTRATION Iranian Registry of Clinical Trials IRCT 20151108024938N2. This trial was approved by the Research Ethics Committee of Mashhad University of Medical Sciences (registration code IR.MUMS.fm.REC.1396.671) (available at https//en.irct.ir/trial/30748 , May 2018).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2023 Document Type: Article Affiliation country: S13063-022-07010-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2023 Document Type: Article Affiliation country: S13063-022-07010-4